Caesar Luo, MD
Retina Specialist · Walnut Creek, CANPI 1669684072
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $210,310 of the $294,116 with a category attached, or 71.5%. 32 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 41.0% of the total. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $589.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$120K
- Alimera Sciences, Inc.$63K
- Novartis$56K
- Genentech USA, Inc.$12K
- Iridex Corporation$10K
- Boehringer Ingelheim International GmbH$8K
- plus $25K from 26 others
Across 307 payments — averaging $3533.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$677K
- Boehringer Ingelheim$127K
- Boehringer Ingelheim International GmbH$118K
- AstraZeneca$118K
- AbbVie$36K
- Boehringer Ingelheim Finland Ky$8K
- plus $403 from 1 others
What the payments were for
- Consulting fees$36,29712%
- Speaking & faculty fees$210,31072%
- Travel & lodging$34,71712%
- Food & beverage$12,7034%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 93 | $120,467 |
| Alimera Sciences, Inc. | 123 | $63,140 |
| Novartis | 67 | $55,649 |
| Genentech USA, Inc. | 49 | $12,342 |
| Iridex Corporation | 4 | $9,765 |
| Boehringer Ingelheim International GmbH | 14 | $7,576 |
| Boehringer Ingelheim | 1 | $4,750 |
| Carl Zeiss Meditec, Inc. | 2 | $4,500 |
| Regeneron | 12 | $2,926 |
| Ocular Therapeutix, Inc. | 8 | $2,457 |
| ANI Pharmaceuticals, Inc. | 11 | $2,293 |
| Eyepoint US, Inc. | 9 | $2,163 |
| Novo Nordisk AS | 4 | $1,942 |
| Alcon | 5 | $619 |
| AbbVie(2 entities) | 19 | $587 |
| Astellas Pharma US Inc | 18 | $543 |
| Dutch Ophthalmic, USA | 2 | $517 |
| Genentech, Inc. | 11 | $466 |
| Apellis Pharmaceuticals, Inc. | 11 | $307 |
| Mallinckrodt Hospital Products Inc. | 7 | $232 |
| Biogen | 8 | $185 |
| Notal Vision, Inc. | 3 | $148 |
| Harrow Eye, LLC | 4 | $125 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Astellas Pharma Global Development | 3 | $75 |
| Bausch & Lomb Americas Inc. | 3 | $72 |
| Optos, Inc. | 2 | $37 |
| Carl Zeiss Meditec USA, Inc. | 1 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Glaukos Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$74,067
- Iluvien$63,175
- EYLEA$48,073
- BEOVU$21,583
- Clarus 700$4,000
- YUTIQ$3,375
- VABYSMO$3,117
- SUSVIMO$2,115
- EVA Ophthalmic Surgical System$500
- CIRRUS HD-OCT$500
- INVELTYS$125
- Rocklatan$122
- Rhopressa$122
- OZURDEX$119
How this compares
$294,116 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 95 | $5,079 |
| Travoprost | 13 | $1,424 |
| MoxifloxacinMoxifloxacin Hcl | 46 | $1,065 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $782 |
| Ketorolac Tromethamine | 33 | $654 |
| Timolol Maleate | 14 | $324 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Walnut Creek
- Roger GoldbergWalnut Creek$1.1M
- Subhransu RayWalnut Creek$16K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
- Esther KimSanta Ana$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.